Provided by Tiger Fintech (Singapore) Pte. Ltd.

CSPC PHARMA

5.530
+0.000
Volume:185.26M
Turnover:1.02B
Market Cap:63.84B
PE:14.08
High:5.660
Open:5.400
Low:5.390
Close:5.530
Loading ...

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Smaller Dividend Than Last Year

Simply Wall St.
·
16 hours ago

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.55 From HK$6.48, Keeps at Buy

MT Newswires Live
·
31 Mar

CSPC Pharmaceutical's Out-Licensing Revenue Likely to be Sizeable Revenue Source -- Market Talk

Dow Jones
·
31 Mar

BRIEF-CSPC Pharmaceutical Posts FY Net Income RMB4,328 Million

Reuters
·
28 Mar

CSPC Pharmaceutical Group FY Revenue RMB 29,009 Million

THOMSON REUTERS
·
28 Mar

BRIEF-CSPC Pharmaceutical Says SYS6040 Obtains Clinical Trial Approval In China From NMPA

Reuters
·
21 Mar

CSPC Pharmaceutical - Sys6040 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval in China From Nmpa

THOMSON REUTERS
·
21 Mar

BRIEF-CSPC Pharmaceutical Says FY Revenue For CSPC Innovation Pharmaceutical RMB1.98 Billion

Reuters
·
21 Mar

CSPC Pharmaceutical - FY Revenue for CSPC Innovation Pharmaceutical RMB1.98 Bln

THOMSON REUTERS
·
20 Mar

Greater China Stocks Close Mixed; Taiwan Leads Gainers

Dow Jones
·
20 Mar

3 Asian Penny Stocks With Market Caps Below US$8B

Simply Wall St.
·
19 Mar

BRIEF-Cspc Pharmaceutical Says JSKN003 Granted Breakthrough Therapy Designation

Reuters
·
18 Mar

CSPC Pharmaceutical's Anti-Tumor Drug Gets US FDA Nod for Clinical Trials

MT Newswires Live
·
14 Mar

BRIEF-CSPC Pharmaceutical Says SYH2051(Selective ATM Inhibitor) Obtains Clinical Trial Approval In U.S.

Reuters
·
13 Mar

CSPC Pharmaceutical - Syh2051 (Selective Atm Inhibitor) Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS
·
13 Mar

An Intrinsic Calculation For CSPC Pharmaceutical Group Limited (HKG:1093) Suggests It's 47% Undervalued

Simply Wall St.
·
08 Mar

CSPC Pharmaceutical Gets China Nod for Tumor Drug Clinical Trial

MT Newswires Live
·
06 Mar

BRIEF-CSPC Pharmaceutical Says JMT108 Obtains Clinical Trial Approval In China

Reuters
·
05 Mar

CSPC Pharmaceutical - Approval From National Medical Products Administration of China

THOMSON REUTERS
·
05 Mar

CSPC Pharmaceutical - Jmt108 (Bi-Functional Fusion Protein Drug) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
05 Mar